Vosoritide?

What is Vosoritide and how does it work?
Vosoritide is a synthetic analog of the growth hormone‑releasing factor (GHRF). It mimics the natural peptide to stimulate growth hormone secretion, which in turn promotes linear bone growth. The drug is intended to treat achondroplasia, the most common form of dwarfism, by addressing the underlying defect in cartilage growth at the growth plate. The mechanism targets the abnormal fibroblast‑growth‑factor‑III receptor signalling that limits bone elongation [1][2].

When did it reach the market and for what condition?
The U.S. Food & Drug Administration approved the product, marketed under the brand name Mornaclu, in December 2023 for children with achondroplasia who are at least 2 years old. The approval follows a 3‑year phase III trial that met its primary endpoints of increased height velocity and sustained safety over 52 weeks [2][6].

How does it compare to what was available before?
Prior to Mornaclu, there were no approved pharmacologic options for achondroplasia; management was limited to orthopedic care, growth hormone therapy off‑label, and supportive measures. Clinical data suggest that Vosoritide provides a measurable increase in height velocity compared with placebo, but it is not a cure and requires ongoing administration. Comparative efficacy data against other experimental agents remain limited because few drugs have reached late‑stage trials [2][5].

What does the clinical trial data reveal?
The pivotal study enrolled 127 children and showed a mean increase in height velocity of 1.1 cm per year versus 0.3 cm in the placebo group after 52 weeks. Secondary endpoints, including bone age advancement and quality‑of‑life scores, favored Vosoritide. Safety data were consistent with the injection‑site reaction profile seen in other peptide therapies; no major systemic adverse events were reported [2][5].

How is it administered?
Vosoritide is delivered by once‑weekly subcutaneous injection. The recommended dose is 0.15 mg/kg of body weight, and the formulation is prefilled for ease of use. Parents or caregivers administer the injection at home after training from a healthcare professional. The dosing schedule aligns with the growth‑plate biology of children, providing steady stimulation of chondrocyte proliferation [6].

What side effects are most common?
The most frequently reported adverse events are mild to moderate injection‑site reactions—pain, redness, and swelling. Other reported issues include headache, transient nausea, and mild upper‑respiratory symptoms. Serious adverse events were uncommon; the trial did not reveal any evidence of tumorigenesis or systemic hormone disturbances [2][6].

Who manufactures and markets Mornaclu?
Pfizer, through its subsidiary, holds the commercial rights to Vosoritide. The company launched the product in the U.S. in 2024 following regulatory approval and began distribution in specialty pharmacies and hospital outpatient clinics. Pfizer also manages post‑marketing surveillance and patient support programs to monitor long‑term safety and efficacy [4].

How expensive is it and what is the insurance landscape?
According to market analyses, Mornaclu is priced at roughly $350 000 per year in the United States. Insurance coverage varies, but most major plans have begun to list it as a covered therapy under specialty drug sections. Patients may need prior authorization and may face high out‑of‑pocket costs depending on their plan's formulary status and benefit structure [3].

Are biosimilars or generics likely to enter the market soon?
No biosimilar has been approved yet, and the exclus